) in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.
Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the Journal said, adding Pfizer would also get about $12 billion in proceeds from a new sale of debt.Reporting by Maria Ponnezhath in Bengaluru; Editing by Mark Potter
Further consolidation that will result in increased drug prices. Republicans will say this is free market principals. Americans will blame Democrats either way.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Pfizer Nears Deal to Combine off-Patent Drug Business With MylanPfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines. Sr. lopez atención sr. lopez..... Se necesitán medicamentos en méxico... Atención jonathanrockoff so that they can raise the price? Ha ha ha. Lower prices. Ha ha ha. Methinks I've heard that before. Ha ha ha.
Fonte: WSJ - 🏆 98. / 63 Consulte Mais informação »
Pfizer Nears Deal to Combine off-Patent Drug Business With MylanPfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines. Sr. lopez atención sr. lopez..... Se necesitán medicamentos en méxico... Atención jonathanrockoff so that they can raise the price? Ha ha ha. Lower prices. Ha ha ha. Methinks I've heard that before. Ha ha ha.
Fonte: WSJ - 🏆 98. / 63 Consulte Mais informação »
There's no business like the arms business: Here's how the top US defense companies did in Q2 earningsNobody spends money on arms like the United States, and it shows in the bottom lines of the biggest defense contractors. 'While the companies’ quarterly performances remained strong, collectively their stocks were largely unchanged. The iShares U.S. Aerospace and Defense ETF was slightly higher for this week after the companies reported. So far this year the benchmark ETF is up nearly 26 percent.'
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »